

AWARD NUMBER: W81XWH-13-1-0302

TITLE: Targeting the UPR to Circumvent Endocrine Resistance in Breast Cancer

PRINCIPAL INVESTIGATOR: Robert Clarke, PhD, DSc

CONTRACTING ORGANIZATION: Georgetown University  
Washington, DC 20057-0001

REPORT DATE: December 2016

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE December 2016		2. REPORT TYPE Final		3. DATES COVERED 15 Sep 2013 - 14 Sep 2016	
4. TITLE AND SUBTITLE Targeting the UPR to Circumvent Endocrine Resistance in Breast Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-13-1-0302	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Robert Clarke, PhD, DSc  E-Mail: clarker@georgetown.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  Georgetown University 37 <sup>th</sup> & O Streets, NW Washington, DC 20057-0001				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT  Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT In this Idea Expansion (IDEX) Grant, we propose that targeting IRE1 in endocrine resistant breast cancer cells with N-(4-Phenoxy-phenyl)-2-(5-pyridin-3-yl-2H-[1,2,4]triazol-3-ylsulfanyl)-acetamide (NPPTA; lead compound), or its analogs, will block pro-survival signaling from the UPR and prevent survival (via pro-survival autophagy and an inhibition of apoptosis). We hypothesize that these effects will be mediated in part by the inhibition of XBP1 splicing and its ability to regulate BCL2 family members and NFkB. Furthermore, a combination of NPPTA and AEs will interact synergistically to selectively kill AE resistant breast cancer cells in vitro and in vivo.					
15. SUBJECT TERMS  Nothing listed					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT  Unclassified	18. NUMBER OF PAGES  10	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT  Unclassified	b. ABSTRACT  Unclassified	c. THIS PAGE  Unclassified			19b. TELEPHONE NUMBER (include area code)

## Table of Contents

	<u>Page</u>
1. Introduction.....	1
2. Keywords.....	1
3. Accomplishments.....	1
4. Impact.....	4
5. Changes/Problems.....	5
6. Products.....	6
7. Participants & Other Collaborating Organizations.....	7
8. Special Reporting Requirements.....	8
9. Appendices.....	None

## INTRODUCTION

In this Idea Expansion (IDEX) Grant, we propose to target IRE1 in endocrine resistant breast cancer cells with N-(4-Phenoxy-phenyl)-2-(5-pyridin-3-yl-2H-[1,2,4]triazol-3-ylsulfanyl)-acetamide (NPPTA; lead compound), or its analogs, will block pro-survival signaling from the UPR and prevent survival (via pro-survival autophagy and an inhibition of apoptosis). We hypothesize that these effects will be mediated in part by the inhibition of XBP1 splicing and its ability to regulate BCL2 family members and NFκB. Furthermore, a combination of NPPTA and AEs will interact synergistically to selectively kill AE resistant breast cancer cells in vitro and in vivo.

## KEYWORDS

Breast Cancer, Drug Development, Endocrine Pathogenesis, Endocrine Resistance

## ACCOMPLISHMENTS

### What were the major goals of the project?

Aim 1: We will use in silico modeling of NPPTA:IRE1 interactions and quantitative structure-activity relationship analyses (QSAR) to develop rationally designed NPPTA analogs with increased potency and optimized pharmacologic properties.

Aim 2: We will determine the ability of NPPTA and its analogs to sensitize responsive breast cancer cells, and re-sensitize resistant cells, to both estrogen withdrawal (analogous to treatment with an AI) and to two different classes of AE (TAM and ICI). These studies will be done initially in vitro, with the strongest candidates being studied in vivo to provide preclinical safety, efficacy, and toxicology data to support later first-in-human studies.


Aim 3: We will explore the mechanism(s) of action of NPPTA and its analogs in inducing cell death, focusing initially on its effects on BCL2 family members and NFκB. We will use high throughput transcriptome analyses to study the effects of NPPTA (or its analogs) on cell survival signaling.

### What was accomplished under these goals?

In the final year of the IDEX award, we resolved the issue with insolubility of our lead compound, NPPTA and its analog, JS-1-20 for testing *in vivo*. Through a fee-for-service collaboration with Southwest Research Institute (SwRI, San Antonio, TX), we were able to make tosylic acid (TsOH) soluble salts of both compounds.


### Prodrug Synthetic chemistry

Our initial synthetic efforts in the NPPTA project are to generate gram quantities of **NPPTA** and **JS-20** as seen in Figure 1.




**Figure 1. Target analogs for further analysis**

Our synthetic plan to generate the initial targets will utilize a converget route that introduces the anilino bi-aryl ether (**1**) in the latter stages as summarized in Scheme 1. This synthetic strategy favors diversity on the bi-aryl ether moiety of the target analogs. This plan requires the preparation of gram quantities of acid **2**.




**Scheme 1. Proposed synthesis of NPPTA and JS - 20**

We have generated the heterocycle **6** in quantities necessary to generate 5 g of the two target analogs. The route is shown in Scheme 2.



**Scheme 2. Synthesis of triazole heterocycle 6**

During the past week we developed a method to generate the ester intermediate **7** in moderate yield as seen in Scheme 3. In addition, the acid **8** was generated and we are currently attempting to generate NPPTA in small scale. These studies are expected to generate NPPTA which we will characterize and compare versus the authentic sample. These studies are expected to be completed in the coming week.




**Scheme 3. Proposed synthesis of NPPTA**

Our goal in this project is to prepare five grams of **NPPTA** and **JS20** as seen in Figure 1. Both compounds possess anti-cancer properties and will be evaluated *in vivo* as the toxic acid salts.

**Scale-up Synthetic chemistry for TsOH salts of NPPTA and JS20:** Our synthetic plan to generate the target analogs utilizes a converget route that introduces the anilino bi-aryl ether (**1** and **2**) in the latter stages as summarized in Scheme 1. This synthetic strategy favors diversity at the bi-aryl ether moiety of the target analogs. This plan requires the preparation of gram quantities of acid chloride **2**.

The preparation of the key acid chloride **2** was prepared as described in Scheme 2. Selective alkylation of commercially available **3** (Sigma/Aldrich) using ethylbromoacetate furnished the ethylester intermediate **4**. Ester saponification followed by treatment with thionylchloride furnished the key acid chloride intermediate in excellent yield.


The successful preparation of **2** set up the final amide coupling step with the desired analines as described in Scheme 1. The preparation of **JS20** required the preparation of aniline **1** (X = CF<sub>3</sub>) and its preparation was achieved as seen in Scheme 3. SNAr chloride displacement was accomplished in moderate yield to provide the aniline **8**.




**Scheme 4. Synthesis of aniline 8**

The final steps in the preparation of **NPPTA** and **JS20** was accomplished as described in Scheme 4. Treatment of acid **2** with analines **9** and **8** in pyridine furnished the target amides in moderate yield. Analysis of the targets verified clean formation the desired products (<sup>1</sup>H NMR and LCMS). The free bases are converted to the tosyl acid salts (1.0 equiv, DCM-MeOH) to provide the target salts (NPPTA-TsOH; JS-20-TsOH). The target amounts (5 g each) were completed and shipped on September 20, 2016.

**NPPTA-TsOH and JS20-TsOH salts significantly decreased cell proliferation in cancer cells but not in non-malignant cells:** LCC1 (sensitive) and LCC9 (antiestrogen resistant) were grown in phenol red-free IMEM with 5% charcoal-stripped calf serum (CCS) at 8000 cells per well in 96-well plates. 24 h later, cells were treated with vehicle alone (0.5% DMSO) or 5, 10, 15 or 20 μM of NPPTA-TsOH or JS20-TsOH for 72 h. After treatment, media were removed, and plates were stained with a solution containing 0.5% crystal violet and 25% methanol, rinsed, dried overnight, and resuspended in citrate buffer (0.1 M sodium citrate in 50% ethanol). Intensity of staining, assessed at 570 nm and quantified using a VMax kinetic microplate reader (Molecular Devices Corp., Menlo Park, CA), is directly proportional to cell number. Our data shows that NPPTA-TsOH treatment for up to 20 μM decreased cell proliferation in LCC1 and LCC9 cells but did not affect proliferation in non-malignant MCF10A (breast epithelial cells) or HFF1 (human foreskin epithelial cells). Similarly, JS20-TsOH showed increased sensitivity in LCC1 and LCC9 cells compared with MCF10A or HFF1 cells (**Figure 2**).



**NPPTA-TsOH** **LCC1** **and JS20-TsOH salts significantly** **LCC9** **decreased tumor**  
**size:** Five week old ovariectomized athymic nude mice (Harlan, Fredrick, MD) were injected orthotopically with  $1.0 \times 10^6$  LCC1/LCC9 cells in 50% Matrigel into mammary fat pads. We tested the efficacy of NPPTA-TsOH and JS-1-20-TsOH in LCC1 and LCC9 xenograft models in athymic nude mice. Total 30 (5 mice per group with 2 tumors per mouse=10 tumors per group: LCC1 and LCC9 for vehicle, NPPTA or JS-1-20) 5-week of nude mice were inoculated with  $1 \times 10^7$  cells. When tumors were about 30 mm<sup>2</sup> in size, mice were injected (i.p.) with 20mg/kg of NPPTA-TsOH, JS-1-TsOH or



**Figure 3:** Growth of LCC1 and LCC9 xenografts was inhibited by NPPTA-TsOH and JS20-TsOH. N=10 tumors per group. Error bars are  $\pm$  SE.

vehicle alone (30% Propylene glycol+5% Tween 80) 5 days a week for 3 weeks. Tumors were measured once a week. Interestingly, our data shows (**Figure 3**) that while both NPPTA and JS-1-20 significantly decreased growth of LCC1 tumors at 3 week post-treatment compared with vehicle alone, only JS-1-20, but not NPPTA, significantly decreased growth of LCC9 tumors at 3 weeks compared with vehicle alone.

**Possible targets for NPPTA-TsOH and JS20-TsOH:** While NPPTA was originally proposed to target the unfolded protein response (UPR) sensor IRE1alpha *in silico*, our *in vitro* data did not confirm IRE1alpha's kinase or endoribonuclease activity to be inhibited by NPPTA (or JS20). It was noted by our team that the structure of NPPTA may suggest a kinase inhibitor function. A kinase screening platform (KinomeScan, DiscoverX) that has a panel of 468 known kinases identified the following hits for NPPTA-TsOH and JS20-TsOH:

NPPTA-TsOH: **c-KIT<PDGFRB<FLT-3**

JS20-TsOH: **MEK6<NEK1**

**Future directions and publication(s):** Currently, we are conducting the validation studies using siRNA for c-KIT and other possible targets identified above. The possible targets identified above are of interest because c-KIT, PDGFRB, FLT-3 are potential anti-cancer targets in various cancer types (PMID: 27128408; PMID: 27944502; PMID: 27949996).

**What opportunities for training and professional development has the project provided?**

Dr. Ayesha Shajahan-Haq, PhD, is a junior faculty member (co-investigator) who supervised the work for this project. She has now transitioned to becoming an independent investigator.

**How were the results disseminated to communities of interest?**

US Appl. No. 14/009,969 as previously reported; nothing additional to report.

**What do you plan to do during the next reporting period to accomplish the goals?**

Not applicable.

**IMPACT**

- **What was the impact on the development of the principal discipline(s) of the project?**

- *If there is nothing significant to report during this reporting period, state "Nothing to Report."*
- *Describe how findings, results, techniques that were developed or extended, or other products from the project made an impact or are likely to make an impact on the base of knowledge, theory, and research in the principal disciplinary field(s) of the project. Summarize using language that an intelligent lay audience can understand (Scientific American style).*

We were not able to validate whether NPPTA and JS20 were indeed targeting IRE1alpha activation in the UPR. In the last year, we were able to generate soluble salts of these compounds and showed that both salts inhibited growth of LCC1 and LCC9 tumors in vivo. In vitro studies showed that NPPTA and JS20 TsOH salts did not inhibit growth of normal cells. We were able to identify possible new targets of NPPTA (c-KIT, PDGFRB, FLT3) and JS20 (MED6, NEK1). All of these molecules are promising targets in various cancer types and may provide useful tools for the research community. Therefore, we look forward to further validation studies of the above mentioned targets and publishing our findings within the next 6 months.

- **What was the impact on other disciplines?**

Nothing to Report

- **What was the impact on technology transfer?**

US Appl. No. 14/009,969

- **What was the impact on society beyond science and technology?**

Nothing to Report

**CHANGES/PROBLEMS****Changes in approach and reasons for change**

None

**Actual or anticipated problems or delays and actions or plans to resolve them**

None

**Changes that had a significant impact on expenditures**

None



**Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**

None

**Significant changes in use or care of human subjects**

None

**Significant changes in use or care of vertebrate animals.**

None

**Significant changes in use of biohazards and/or select agents**

None

## **PRODUCTS**

**Publications, conference papers, and presentations**

Nothing to Report

**Website(s) or other Internet site(s)**

Nothing to Report

**Technologies or techniques**

Nothing to Report

**Inventions, patent applications, and/or licenses**

Nothing to Report

**Other Products**

Nothing to Report

## **PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS**

### **• What individuals have worked on the project?**

- *Provide the following information for: (1) PDs/PIs; and (2) each person who has worked at least one person month per year on the project during the reporting period, regardless of the source of compensation (a person month equals approximately 160 hours of effort). If information is unchanged from a previous submission, provide the name only and indicate "no change."*

***Example:***

Name:	<i>Robert Clarke, PhD, DSc</i>
Project Role:	<i>Principal Investigator</i>
Researcher Identifier (e.g. ORCID ID):	<i>ORCID: 0000-0002-9278-0854</i>
Nearest person month worked:	<i>1</i>
Contribution to Project:	<i>Dr. Clarke is the PI of this project and as such is primarily responsible for the overall direction and operation of this application. He directs, coordinates and integrates the proposed studies, prepares reports and manuscripts to disseminate results.</i>
Funding Support:	<i>N/A</i>

Name:	<i>Ayesha Shajahan-Haq</i>
Project Role:	<i>Co-Investigator</i>
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	<i>4</i>
Contribution to Project:	<i>Dr. Shajahan-Haq supervises the research assistant and helps perform the experiments specified in the proposal. She also participates in the preparation and presentation of the reports/results and the preparation of manuscripts for publication.</i>
Funding Support:	<i>N/A</i>

- **Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?**

Nothing to Report

- **What other organizations were involved as partners?**

Nothing to Report

## **SPECIAL REPORTING REQUIREMENTS**

None

## **APPENDICES**

None.